Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences announces initial shipments of its next-generation PCT System

Pressure BioSciences, Inc. announces the initial shipments of its recently released, next-generation pressure cycling technology-based instrument, the Barocycler 2320EXTREME
Pressure BioSciences announces initial shipments of its next-generation PCT System
Three Barocycler 2320EXTREME devices destined near Sydney

Pressure BioSciences, Inc. (OTCMKTS:PBIO) announced the initial shipments of its recently released, next-generation pressure cycling technology ("PCT")-based instrument, the Barocycler 2320EXTREME on Thursday. 

Five instruments were recently purchased and delivered: one to an Ivy-league school with a rich history in life sciences research, one to the company's exclusive distributor in China, and the remaining three to the Children's Medical Research Institute ("CMRI") near Sydney Australia.

The instruments purchased by CMRI will be used in cancer research studies by the newly established Australian Cancer Research Foundation International Centre for the Proteome of Cancer ("ProCan"), located in the CMRI facility.

ProCan has announced plans to analyse approximately 70,000 cancer tumor samples over the next seven years with state-of-the-art protein profiling instruments and other tools. Data from their studies are expected to enable discoveries around the causes of cancer, provide guidance on cancer treatment options, and generate standard operating procedures that can be used in cancer testing laboratories worldwide.

In their studies, ProCan will combine PBI's new Barocycler 2320EXT system for sample preparation with SCIEX's SWATH data independent-acquisition mass spectrometry workflow on Triple TOF 6600 Systems.  SCIEX is a global leader in life science analytical technologies. 

In January 2016, PBI and SCIEX announced an exclusive, two-year, worldwide co-marketing agreement under which PBI and SCIEX will co-promote PBI's PCT systems with SCIEX's SWATH-based proteomics workflows.

In his 2016 State-of-the-Union message, President Barack Obama introduced the $1bn 'Cancer Moonshot' initiative, with a goal to accelerate research in cancer, to break down existing barriers that stymie progress, and to support other changes that will improve the ability to prevent, detect, treat, and cure cancer. Vice-President Biden was asked to lead this effort.

On July 16, the White House named ProCan as one of four preeminent cancer centers in Australia chosen to collaborate with the US National Cancer Institute in the "Cancer Moonshot" initiative.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

Widecells
September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use